Royalty Pharma (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced a funding agreement of up to $500M to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-‘408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share
- Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
- Royalty Pharma Announces Planned Legal Leadership Transition
- Royalty Pharma Gains From FDA Approval of MYQORZO
- Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib